Why the study?
Does transcatheter aortic valve replacement with the self-expanding ACURATE neo2 device reduce paravalvular aortic regurgitation?
Does transcatheter aortic valve replacement with the self-expanding ACURATE neo2 device reduce paravalvular aortic regurgitation?
The ACURATE neo2 TAVR device is associated with reduced paravalvular aortic regurgitation, particularly in patients with heavy aortic valve calcification.
No takes yet. Share an insight, caveat, or question.
May favor ACURATE neo2 in heavy calcification to reduce paravalvular AR; leaves open randomized confirmation.
Scotti et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: